We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
GSK Gets CHMP Nod for Blenrep Combos in Multiple Myeloma
Read MoreHide Full Article
GSK plc (GSK - Free Report) announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has rendered a positive opinion recommending approval for the Blenrep (belantamab mafodotin) combination therapy to treat relapsed or refractory multiple myeloma.
The CHMP recommended the approval of Blenrep in combination with J&J’s Velcade (bortezomib) plus dexamethasone for treating relapsed/refractory multiple myeloma in adult patients who have received at least one prior therapy. The CHMP also recommended the approval of Blenrep in combination with Bristol Myers’ Pomalyst (pomalidomide) plus dexamethasone for the treatment of relapsed/refractory multiple myeloma in adult patients who have received at least one prior therapy, including Revlimid (lenalidomide).
The European Commission will now review the CHMP’s opinion, and a decision from the regulatory body is expected in the third quarter of 2025.
The positive CHMP opinion for the Blenrep combo was based on data from the III DREAMM-7 and DREAMM-8 studies.
Data from both studies showed that treatment with the Blenrep combo led to statistically significant and clinically meaningful improvements in progression-free survival (PFS) versus standard-of-care as well as overall survival versus triplet combinations in relapsed or refractory multiple myeloma patients.
The safety and tolerability of Blenrep combinations in both studies were generally consistent with the known profiles of the individual agents.
GSK's Stock Performance
Year to date, shares of GSK have rallied 14.3% against the industry’s decline of 5.5%.
Image Source: Zacks Investment Research
GSK's Blenrep Combo Nearing a Potential Nod in the United States
GSK’s biologics license application seeking approval for the Blenrep combination therapy to treat relapsed or refractory multiple myeloma is also under review in the United States.
A final decision from the FDA is expected on July 23, 2025.
Blenrep combinations were approved in the United Kingdom and Japan in April and May 2025, respectively.
Besides the United States and the European Union, the Blenrep combinations are also currently under review in China, Canada and Switzerland.
We remind investors that in November 2022, Blenrep was withdrawn from the U.S. market after the failure of GSK’s phase III confirmatory study, DREAMM-3, which evaluated Blenrep in patients with relapsed or refractory multiple myeloma. The study failed to meet its primary endpoint of PFS, thereby failing to meet the FDA’s accelerated approval regulations.
Consequently, Blenrep monotherapy as a treatment for relapsed or refractory multiple myeloma was also withdrawn from the EU market.
Now that the Blenrep combo has already been approved in Japan and the United Kingdom and is nearing a potential approval in the United States and European Union, GSK hopes to bring the drug back to the market for patients with this dreadful disease.
In the past 60 days, estimates for Halozyme’s earnings per share have increased from $5.02 to $5.23 for 2025. During the same time, earnings per share estimates for 2026 have increased from $6.56 to $6.77. Year to date, shares of HALO have risen 14.1%.
HALO’s earnings beat estimates in each of the trailing four quarters, with the average surprise being 17.60%.
In the past 60 days, estimates for Lexicon’s loss per share have narrowed from 37 cents to 32 cents for 2025. During the same time, loss per share estimates for 2026 have narrowed from 35 cents to 31 cents. Year to date, shares of LXRX have lost 10.7%.
LXRX’s earnings beat estimates in three of the trailing four quarters and missed the same on the remaining occasion, delivering an average surprise of 11.97%.
In the past 60 days, estimates for Amarin’s loss per share have narrowed from $5.33 to $3.48 for 2025. During the same time, loss per share estimates for 2026 have narrowed from $4.13 to $2.67. Year to date, shares of AMRN have gained 14.5%.
AMRN’s earnings beat estimates in two of the trailing four quarters, matched once and missed the same on the remaining occasion, delivering an average surprise of 29.11%.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
GSK Gets CHMP Nod for Blenrep Combos in Multiple Myeloma
GSK plc (GSK - Free Report) announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has rendered a positive opinion recommending approval for the Blenrep (belantamab mafodotin) combination therapy to treat relapsed or refractory multiple myeloma.
The CHMP recommended the approval of Blenrep in combination with J&J’s Velcade (bortezomib) plus dexamethasone for treating relapsed/refractory multiple myeloma in adult patients who have received at least one prior therapy. The CHMP also recommended the approval of Blenrep in combination with Bristol Myers’ Pomalyst (pomalidomide) plus dexamethasone for the treatment of relapsed/refractory multiple myeloma in adult patients who have received at least one prior therapy, including Revlimid (lenalidomide).
The European Commission will now review the CHMP’s opinion, and a decision from the regulatory body is expected in the third quarter of 2025.
The positive CHMP opinion for the Blenrep combo was based on data from the III DREAMM-7 and DREAMM-8 studies.
Data from both studies showed that treatment with the Blenrep combo led to statistically significant and clinically meaningful improvements in progression-free survival (PFS) versus standard-of-care as well as overall survival versus triplet combinations in relapsed or refractory multiple myeloma patients.
The safety and tolerability of Blenrep combinations in both studies were generally consistent with the known profiles of the individual agents.
GSK's Stock Performance
Year to date, shares of GSK have rallied 14.3% against the industry’s decline of 5.5%.
Image Source: Zacks Investment Research
GSK's Blenrep Combo Nearing a Potential Nod in the United States
GSK’s biologics license application seeking approval for the Blenrep combination therapy to treat relapsed or refractory multiple myeloma is also under review in the United States.
A final decision from the FDA is expected on July 23, 2025.
Blenrep combinations were approved in the United Kingdom and Japan in April and May 2025, respectively.
Besides the United States and the European Union, the Blenrep combinations are also currently under review in China, Canada and Switzerland.
We remind investors that in November 2022, Blenrep was withdrawn from the U.S. market after the failure of GSK’s phase III confirmatory study, DREAMM-3, which evaluated Blenrep in patients with relapsed or refractory multiple myeloma. The study failed to meet its primary endpoint of PFS, thereby failing to meet the FDA’s accelerated approval regulations.
Consequently, Blenrep monotherapy as a treatment for relapsed or refractory multiple myeloma was also withdrawn from the EU market.
Now that the Blenrep combo has already been approved in Japan and the United Kingdom and is nearing a potential approval in the United States and European Union, GSK hopes to bring the drug back to the market for patients with this dreadful disease.
GSK's Zacks Rank & Other Stocks to Consider
GSK currently carries a Zacks Rank #2 (Buy).
Some other top-ranked stocks in the biotech sector are Halozyme Therapeutics (HALO - Free Report) , Lexicon Pharmaceuticals (LXRX - Free Report) and Amarin (AMRN - Free Report) , each carrying a Zacks Rank #2 at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
In the past 60 days, estimates for Halozyme’s earnings per share have increased from $5.02 to $5.23 for 2025. During the same time, earnings per share estimates for 2026 have increased from $6.56 to $6.77. Year to date, shares of HALO have risen 14.1%.
HALO’s earnings beat estimates in each of the trailing four quarters, with the average surprise being 17.60%.
In the past 60 days, estimates for Lexicon’s loss per share have narrowed from 37 cents to 32 cents for 2025. During the same time, loss per share estimates for 2026 have narrowed from 35 cents to 31 cents. Year to date, shares of LXRX have lost 10.7%.
LXRX’s earnings beat estimates in three of the trailing four quarters and missed the same on the remaining occasion, delivering an average surprise of 11.97%.
In the past 60 days, estimates for Amarin’s loss per share have narrowed from $5.33 to $3.48 for 2025. During the same time, loss per share estimates for 2026 have narrowed from $4.13 to $2.67. Year to date, shares of AMRN have gained 14.5%.
AMRN’s earnings beat estimates in two of the trailing four quarters, matched once and missed the same on the remaining occasion, delivering an average surprise of 29.11%.